However, CD20 is often only expressed at low levels on CLL cells, making it a suboptimal therapeutic target.33 Since CXCR4 is abundantly expressed by CLL cells,34 targeting this chemokine receptor may have more therapeutic potential. Here, CXCR4 is linked to B-cell chronic lymphocytic leukemia.